Zealand Pharma Sinks 25% on Survodutide Safety Fears

CNBC reported Monday that shares of Zealand Pharma, the Danish obesity drugmaker, tumbled as much as 26% after late-stage clinical data for its experimental treatment survodutide raised serious concerns about patient tolerability. The stock was last seen down roughly 24%, extending a year-to-date decline of nearly 50%.

What the Survodutide Data Actually Showed

The trial results were a study in contradictions. Survodutide met its primary endpoints, a result that would normally encourage investors. But the discontinuation numbers told a harder story. Nearly one in five patients, around 19%, withdrew from the study because of gastrointestinal problems. The placebo group saw a dropout rate of just 2.9%. More than 40% of participants reported vomiting at some point during the trial.

Analysts at Barclays flagged the gap immediately. “Safety/tolerability remains the key issue,” the bank wrote in a note published Monday. The concern is not efficacy. It is whether patients will stick with the drug long enough for it to work commercially.

A Competitive Landscape That Offers Little Room for Error

Rivals tirzepatide and semaglutide, already approved and widely prescribed, have set a high bar for tolerability. Citi analysts were direct in their assessment. A 19% discontinuation rate driven by adverse events is not a minor statistical footnote, they wrote, adding that nausea, vomiting, diarrhea, and constipation levels in the survodutide trial sat well above what they regard as commercially viable against those established alternatives.

Background: Zealand Has Had a Bruising Year

Monday’s sell-off is not Zealand’s first of this magnitude in 2026. Roughly three months ago the company suffered its worst single-day stock decline on record. That earlier move was triggered by disappointing weight-loss figures from a separate experimental obesity drug. Together, the two episodes have wiped out close to half the company’s market value since January.

Zealand’s CEO has previously told CNBC that the industry needs to move past what he described as a fixation on the “weight loss Olympics,” arguing that broader metabolic benefits deserve more attention from investors and clinicians alike.

What Comes Next for Zealand

The commercial case for survodutide now hinges on whether the side-effect profile can be managed through dosing adjustments or patient selection. Analysts have not ruled out a path forward, but the burden of proof has risen sharply. Investors will be watching for any further data readouts and for whether the company updates its guidance in response to Monday’s reaction.

Read Next: Fed Holds Rates Steady as Inflation Data Keeps Policy Path Uncertain